Imunon, Inc.
$3.1
▲
7.69%
2026-04-21 07:29:01
imunon.com
NCM: IMNN
Explore Imunon, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$12.36 M
Current Price
$3.1
52W High / Low
$41.22 / $2.52
Stock P/E
—
Book Value
$2.42
Dividend Yield
—
ROCE
-191.16%
ROE
-2.56%
Face Value
—
EPS
$-6.83
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
2.12
Debt / Equity
14.29
Current Ratio
2.32
Quick Ratio
2.32
Forward P/E
-0.93
Price / Sales
—
Enterprise Value
$3.68 M
EV / EBITDA
-0.26
EV / Revenue
—
Rating
Strong Buy
Target Price
$21.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Sensei Biotherapeutics, Inc. | $31.39 | — | $42.07 M | — | -119.5% | -74.01% | $36.76 / $5.25 | $18.24 |
| 2. | Equillium, Inc. | $2.01 | — | $127.09 M | — | -81.63% | -94% | $2.7 / $0.27 | $0.47 |
| 3. | Lantern Pharma Inc. | $2.76 | — | $27.91 M | — | -275.14% | -1.24% | $5.74 / $1.11 | $0.58 |
| 4. | Absci Corporation | $3.95 | — | $547.82 M | — | -64.8% | -62.5% | $5.23 / $2.24 | $1.25 |
| 5. | AgomAb Therapeutics NV | $10.79 | — | $0.28 M | — | -24.35% | -27.25% | $17.45 / $9 | $-7,123.4 |
| 6. | Axsome Therapeutics, Inc. | $184.13 | — | $9.35 B | — | -54.42% | -2.52% | $191.5 / $96.09 | $1.74 |
| 7. | Grace Therapeutics, Inc. | $4.59 | — | $71.03 M | — | -23.81% | -10.22% | $5.18 / $2 | $4.19 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -4.26 M | -3.48 M | -2.77 M | -4.15 M | -4.15 M | — |
| Net Profit | -4.22 M | -3.43 M | -2.74 M | -4.1 M | -4.06 M | — |
| EPS in Rs | -1.08 | -0.87 | -0.7 | -1.05 | -1.03 | -3.76 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.5 M |
| Operating Profit | -14.65 M | -19.13 M | -21.03 M | -24.92 M |
| Net Profit | -14.5 M | -18.62 M | -19.51 M | -35.9 M |
| EPS in Rs | -3.7 | -4.75 | -4.97 | -9.15 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 12.29 M | 9.72 M | 21.92 M | 43.98 M |
| Total Liabilities | 5.23 M | 5.47 M | 8.53 M | 14.65 M |
| Equity | 7.06 M | 4.24 M | 13.39 M | 29.33 M |
| Current Assets | 10.72 M | 8.01 M | 18.24 M | 36.78 M |
| Current Liabilities | 4.62 M | 4.79 M | 7.39 M | 10.04 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -13.9 M | -18.85 M | -19.02 M | -23.1 M |
| Investing CF | -0.28 M | 9.83 M | 11.01 M | 8.28 M |
| Financing CF | 17.09 M | 9.06 M | -3.64 M | 6.72 M |
| Free CF | -14.18 M | -18.88 M | -19.47 M | -23.36 M |
| Capex | -0.28 M | -0.03 M | -0.45 M | -0.27 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | 4.58% | 45.64% | — | — |
| Profit Margin % | — | — | -7179.65% | — |
| Operating Margin % | — | — | -4984.31% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -6341% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-08-07 | 1:1.15 |
| 2025-07-25 | 1:0.0666667 |
| 2022-03-01 | 1:0.0666667 |